
ESOCAP ANNOUNCES AUTHORISATION OF CAPITAL INCREASE BY EXTRAORDINARY GENERAL ASSEMBLY AND SUCCESSFUL CLOSING OF ITS PRIVATE PLACEMENT OFFERING



Basel, Switzerland, April 30, 2019

EsoCap AG announced that a capital increase has been authorized by the Extraordinary General Assembly, held on April 11, 2019, followed by successful completion of a private placement financing. The proceeds of the private placement will be used to complete a clinical proof-of-concept trial in eosinophilic esophagitis (EoE).

“We are delighted to have secured the financial resources to advance EsoCap’s innovative technology rapidly toward the clinic,” said Isabelle Racamier, EsoCap AG CEO. “This financing allows EsoCap AG to run the planned clinical trial in EoE and to conduct feasibility studies in other esophageal diseases.”

The private financing round includes investments from existing, as well as new, investors with a strong entrepreneurial and life sciences background. This funding is instrumental, as it gives a solid financial position while moving into the clinical development phase.

About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases through development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve, due to ultra-short transit times, with less than two seconds from mouth to stomach.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit www.esocapbiotech.com.

Contact:

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland

isabelle.racamier@esocapbiotech.com